secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001437749-25-003765
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss
------------------------------------------------------------------------

- Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).
- Operating income $0.2M vs operating loss $0.5M in prior year quarter; six-month op income $0.7M.
- Net income $0.1M ($0.00 EPS) vs net loss $0.4M ($(0.01) EPS) in prior year quarter.
- Two largest contract manufacturing customers represented ~82% of total revenue in the six-month period.
- Co-CEOs cite customer base expansion and core business focus as drivers of revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774925003765/0001437749-25-003765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774925003765/inbp20250211_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-003765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer